United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. Our lead product, Remodulin, is approved in the U.S. and various countries around the world for both continuous subcutaneous and continuous intravenous infusion for the treatment of pulmonary arterial hypertension (PAH). In addition to prostacyclin analogs like Remodulin, United Therapeutics develops Glycobiological Antiviral Agents for the treatment of infectious diseases, such as Hepatitis C. For more information about United Therapeutics' pipeline, click here

To receive press releases, quarterly and annual SEC filings, please click here.

Current Press Releases

Oct 29, 2009
United Therapeutics Corporation Reports Third Quarter 2009 Financial Results

Oct 22, 2009
United Therapeutics Corporation to Announce Third Quarter 2009 Financial Results Before Market Open on Thursday, October 29, 2009

more »

Events

Dec 15, 2009
2nd Annual DB-BIOTECH BOSTON CONFAB

Jan 11, 2010
28th Annual J.P. Morgan Healthcare Conference

more »